Pfizer Enters Obesity Race with 6.8% Dividend Yield

While the debate around Novo Nordisk (NVO) and its GLP-1 drugs like Wegovy and Ozempic continues, reality is setting in with less attractive numbers than headlines suggest. In this context, Pfizer (PFE) emerges as a new player in the obesity drug race, with a promising pipeline and a 6.8% dividend yield.

Pfizer's Obesity Pipeline Details

Pfizer is developing new obesity treatments within the GLP-1 class, leveraging its extensive pharmaceutical expertise. The company has not yet disclosed specific clinical trial timelines or potential launch dates, but analysts see significant revenue potential if the treatments succeed.

Dividend Yield as a Competitive Advantage

Pfizer currently offers a 6.8% dividend yield, well above the sector average. This yield makes the stock attractive for income-seeking investors while waiting for pipeline results.

Market Context

Novo Nordisk shares have recently declined following reports of slowing sales growth for obesity drugs and increased competition. In contrast, Pfizer is still in early stages, but its strong dividend provides relative downside protection.

What This Means for Investors

Pfizer stock offers an opportunity for investors seeking exposure to the obesity drug sector with a high dividend income. However, risks include early-stage development and intense competition from companies like Novo Nordisk and Eli Lilly.